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Abstract
Rationale: Chronic obstructive pulmonary disease (COPD) is a
common cause of morbidity and associated with a significant burden
of comorbidities. Although anemia is associated with adverse
outcomes in COPD, its contribution to outcomes in individuals with
other comorbid chronic diseases is not well understood.
Objectives: This study examines the association of anemia
with outcomes in a large, well-characterized COPD cohort,
and attempts to understand the contribution of anemia to outcomes
and phenotypes in individuals with other comorbidities.
Methods: Participants with COPD from SPIROMICS (the
Subpopulations and Intermediate Outcome Measures in COPD
Study) were analyzed in adjusted models to determine the
associations of normocytic anemia with clinical outcomes,
computed tomographic measures, and biomarkers. Analysis was
additionally performed to understand the independence and
possible interactions related to cardiac and metabolic comorbidities.
Results:A total of 1,789 individuals with COPD from SPIROMICS
had data on hemoglobin, and of these 7.5% (n = 135) were found to
have normocytic anemia. Anemic participants were older with
worse airflow obstruction, a higher proportion of them were African
Americans, and they had a higher burden of cardiac and metabolic
comorbidities. Anemia was strongly associated with 6-minute walk
distance (b,261.43; 95% confidence interval [CI],285.11 to237.75),
modified Medical Research Council dyspnea questionnaire (b, 0.27;
95% CI, 0.11–0.44), and St. George’s Respiratory Questionnaire
(b, 3.90; 95% CI, 1.09–6.71), and these adjusted associations were
stronger among those with two or more cardiac and metabolic
comorbidities. Anemia was associated with higher levels of serum
C-reactive protein, soluble receptor for advanced glycosylation end-
products, and epithelial cadherin-1, findings that persisted when in
those with a high burden of comorbidities.
Conclusions: Anemia is associated with worse exercise capacity,
greater dyspnea, and greater disease severity among adults with
COPD, particularly among those with comorbid chronic cardiac and
metabolic diseases. The biomarkers found in anemic individuals
suggest inflammation, lung tissue injury, and oxidative stress as
possible pathways for the adverse correlations of anemia with
outcomes in COPD; however, substantial further study is required to
better understand these potential mechanisms.
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Chronic obstructive pulmonary disease
(COPD) is the third leading cause of death
in the United States (1) and is associated
with a significant burden of comorbidities
(2). The estimated prevalence of anemia has
varied between studies but has ranged
between 7.5 and 33% in COPD (3). Ferrari
and colleagues found that anemic patients
with COPD report a worse quality of life,
lower exercise capacity, and increased
dyspnea compared with nonanemic patients
with COPD (4). Others have also described
a higher risk for mortality (5, 6) and
health care utilization (7) in individuals with
COPD also having anemia. In addition,
there has been an increasing focus on
describing a phenotype of individuals with
COPD having a high burden of comorbid
chronic disease (8–10) and systemic
inflammation. The role of anemia in
contributing to phenotypic features and
adverse outcomes in this subgroup of
individuals with a high burden of comorbid
cardiac and metabolic disease has not clearly
been elucidated.
SPIROMICS (Subpopulations and
Intermediate Outcome Measures in COPD
Study) is an ideal population in which to
study the association of anemia with COPD
morbidity, due to the extensive phenotyping
data which were collected. The purpose
of this study is to evaluate the association
of anemia and phenotypic characteristics
including clinical and biologic markers
among a contemporary cohort of individuals
with COPD. We hypothesized that those
individuals with COPD having comorbid
anemia would have more systemic
inflammation, dyspnea, and exercise
limitation compared with those with normal
hemoglobin concentrations.
Methods
SPIROMICS (11) is a multicenter prospective
study of current and former smokers (>20
pack-years) with and without obstructive
lung disease and of nonsmokers without
obstructive lung disease (age, 40–80 yr)
enrolled between November 2010 and July
2015 and monitored quarterly for up
to 3 years. The original goals of the study
were to identify subgroups of individuals
with COPD to develop future targeted
therapeutic strategies and treatments. This
study includes all individuals with COPD
including current and former smokers
with FEV1/FVC less than 0.70 (FEV1> 50%
predicted, n = 1,193; and FEV1, 50%
predicted, n = 596).
Anemia Characterization
Data on hemoglobin concentration, reported
as grams per deciliter (g/dl), from complete
blood counts drawn at the baseline visit,
were analyzed. Normocytic anemia was
defined as a hemoglobin concentration
below 12 g/dl if female and below 13 g/dl
if male while also having mean corpuscular
volume in the normal range (80–100 fl) (12).
Anemic individuals with abnormal
mean corpuscular volume were excluded
from this analysis given the low
prevalence of microcytic and macrocytic




multidetector helical computed tomography
(CT) at full inspiration and expiration at
the baseline study visit. Measurements
of interest included percent emphysema
(percent voxels less than 2950 Hounsfield
units in the inspiratory phase), percent
gas-trapping (percent voxels less than2856
Hounsfield units in the expiratory
phase), upper-to-lower lobe ratio of
emphysema, and Pi10 (a measure of
bronchial wall thickening which correlates
to the square root of the wall area of a
hypothetical airway with a 10 mm internal
perimeter) (13).
Biomarker Measurements
Blood was collected and 12 multiplex
platforms and one simplex platform (Myriad-
RBM) were utilized on baseline samples
to analyze 105 biomarkers, which were
preselected on the basis of possible relevance
to COPD (14). Of the 105 biomarkers, a
subgroup (n = 13) of preselected biomarkers
thought to be associated with systemic
inflammation and COPD subphenotyping in
previous analyses was analyzed, including
von Willebrand factor (VWF), vascular
endothelial growth factor (VEGF)-a, tumor
necrosis factor (TNF)-a, IL-15, interferon
(IFN)-g, immunoglobulin A (IgA), C-reactive
protein (CRP), apolipoprotein A-IV (ApoA4),
soluble receptor for advanced glycosylation
endproducts (sRAGE, encoded by the AGER
gene), vascular cell adhesion molecule 1
(VCAM1), superoxide dismutase 1 (SOD1),
sex hormone–binding globulin (SHBG),
and epithelial cadherin 1 (E-cadherin,
CDH1).
Outcomes
Outcomes of interest were respiratory-specific
quality of life (St. George’s Respiratory
Questionnaire [SGRQ]) (15), exercise capacity
(6-min walk distance [6MWD], in meters)
(16), dyspnea (Modified Medical Research
Council [MMRC] questionnaire) (17), and
COPD health status (COPD Assessment Test
[CAT]) (18). Exacerbations in the previous
year were based on participant report of new
prescription of antibiotics and/or steroids,
unscheduled doctor visits, emergency
room visits, and hospitalizations for
COPD exacerbations and frequency
of these instances over the past year.
Severe exacerbations were defined as
events requiring emergency room
visit or hospitalization. In addition to
baseline exacerbation data, available data
regarding prospective exacerbations
from study enrollment to most recent
follow-up contact were analyzed where
available.
Statistical Methods
The cross-sectional associations between
anemic status and outcomes were
analyzed using multivariable linear or
logistic regression models (in which mean
differences and odds ratios were estimated,
respectively). Longitudinal analyses of
exacerbation risk were analyzed as count
data using adjusted zero-inflated negative
binomial regression with an offset for time
to account for individuals’ varying follow-up
time to estimate incidence rate ratios. To
examine whether there was a dose–response
relationship between hemoglobin and
each outcome, hemoglobin was also
examined as a continuous variable in all
models. Individuals with polycythemia were
removed from this analysis because this
represents a separate clinical phenotype.
All models were adjusted for age, sex, race
(African American vs. other), education
(high school education or less vs. more
than high school), FEV1 % predicted,
current smoking, and number of
comorbidities (19). Figures of adjusted
associations of hemoglobin concentration
(continuous) with selected outcomes for
those with hemoglobin below 15 for females
and 17 for males (given the hypothesis
that those with polycythemia represent a
distinct phenotype), modeled continuously,
were constructed using fractional
polynomials to test for linearity. The
point estimates and 95% confidence
interval represent the predicted level of
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the outcome across hemoglobin, which has
been power transformed based on a fractional
polynomialmodel (m = 2)with power selected
from 22, 21, 20.0.5, 0, 0.5, 1, 2, and 3. For
each figure, the best fitting fractional
polynomial model was used, with hemoglobin
transformed to its appropriate power terms.
The predicted levels represent the average
predicted levels with all other covariates held
at their observed values. The plots were drawn
with the Stata package “margincontplot”
(StataCorp), which handles fractional
polynomial transformation for margins
plotting (20).
Given the high prevalence of cardiac
and metabolic comorbidities in the group
with anemia, sensitivity analysis was
performed, repeating models with
adjustment for “cardiometabolic
phenotype,” defined as having two or more
cardiac or metabolic comorbidities
including self-report of hypertension,
coronary heart disease (including self-report
of doctor-diagnosed coronary artery disease,
angina, or heart attack), diabetes, congestive
heart failure (not specific to diastolic or
systolic), stroke, and obesity (defined as body
mass index greater than or equal to 30
kg/m2). To evaluate whether there was a
heightened susceptibility to adverse
outcomes due to anemia among those with
the cardiometabolic phenotype, interaction
terms between anemia and the presence
of this phenotype were included in fully
adjusted models, with a threshold for
significance for reporting of 0.10 (21). The
association of anemia with biomarker
concentrations was analyzed in a similar
manner using unadjusted and adjusted
models as previously described (which also
included adjustment for the batch number
of biomarker run), and interaction terms
for anemia status and the cardiometabolic
phenotypes. Sensitivity analyses were performed
including those with micro- and macrocytic
anemia in the group with anemia for main
analysis.
All analyses were conducted with Stata
12 (22), and the thresholds for statistical
significance formain effects and interactions
were 0.05 and 0.10, respectively (21, 23, 24).
Given that multiple biomarkers were
tested (13 in total), Bonferroni correction was
utilized for biomarker models, with a
threshold for statistical significance of 0.00384.
SPIROMICS was approved by institutional
review boards at each center, and all




Data from 1,789 participants with
COPD and having data on hemoglobin
concentration were analyzed (Table 1). The
prevalence of normocytic anemia was
7.5% (n = 135). Those with anemia had a
slightly higher and more variable red cell
distribution width (RDW) compared with
those without anemia (mean RDW, 14.5
[SD, 2.2] in individuals with anemia
compared with mean RDW, 13.8 [SD, 1.2]
in those with normal hemoglobin). Compared
with those without anemia, those with
anemia were older (mean age, 68.2 [SD,
8.1] vs. 64.9 [SD, 7.1]), had lower lung
function (mean FEV1 % predicted, 56.1 [SD,
24.7] vs. 61.6 [SD, 22.8]), had lower
education attainment (49% with more than
high school education vs. 62%), were more
likely to be African American (30 vs. 14%),
were more likely to have quit smoking (22%
current smokers vs. 35%), and were more
likely to require oxygen supplementation
(37 vs. 19%). Those with anemia had a
higher overall comorbidity burden (count of
comorbidities: 3.6 [SD, 1.7] vs. 2.4 [SD, 1.6])
and in particular a higher prevalence
of cardiac and metabolic comorbidities,
Table 1. Cohort characteristics
Total N = 1,789
Normocytic Anemia Not Anemic
(N = 135; 7.5%) (N = 1,654; 92.5%)
Hemoglobin 11.6 (0.95) 14.6 (1.33)
Red cell distribution width (RDW) 13.8 (1.2) 14.5 (2.2)
Demographics and smoking
Age, yr 68.2 (8.1) 64.9 (7.1)
Female, n (%) 52 (39%) 708 (43%)
More than high school education, n (%) 66 (49%) 1,026 (62%)
African American, n (%) 40 (30%) 229 (14%)
Pack-years 52.7 (25.2) 52.7 (27.7)
Current smoker, n (%) 30 (22%) 575 (35%)
Spirometry, oxygenation, exercise, disease
status
FEV1 % predicted 56.1 (24.7) 61.6 (22.8)
6MWD, m 319.1 (134.9) 398.2 (126.6)
Oxygen use, n (%) 48 (37%) 309 (19%)
Resting oxygen saturation 95.2 (2.6) 94.7 (4.2)
COPD Assessment Test 17.06 (8.02) 15.25 (7.96)
St. George’s Respiratory Questionnaire,
total score
42.93 (18.85) 37.46 (19.81)
MMRC dyspnea score 1.61 (1.21) 1.23 (1.01)
CT measures
% emphysema 12.1 (11.8) 11.1 (11.3)
Upper-to-lower lobe ratio of emphysema 2.36 (4.22) 2.30 (4.62)
Normalized Pi10 0.25 (1.12) 20.0046 (1.01)
Comorbidities
Stroke, n (%) 13 (10%) 63 (4%)
Diabetes, n (%) 28 (21%) 211 (13%)
Reported OSA, n (%) 22 (16%) 307 (19%)
Hypertension, n (%) 77 (57%) 819 (50%)
CHD, n (%) 34 (25%) 299 (18%)
CHF, n (%) 11 (8%) 42 (3%)
Obesity, n (%) 40 (30%) 515 (31%)
Depression, n (%) 38 (28%) 447 (27%)
Anxiety, n (%) 32 (24%) 436 (26%)
GERD, n (%) 44 (33%) 514 (31%)
Allergies, n (%) 29 (21%) 487 (29%)
Asthma, n (%) 27 (20%) 267 (17%)
Comorbidity count 3.6 (1.7) 2.4 (1.6)
Definition of abbreviations: 6MWD= 6-minute walk distance; CHD= coronary heart disease; CHF =
congestive heart failure; COPD = chronic obstructive pulmonary disease; CT = computed tomography;
FEV1 = forced expiratory volume in 1 second; GERD = gastroesophageal reflux disease; MMRC=
ModifiedMedical Research Council; OSA = obstructive sleep apnea; Pi10 = square root of the wall area
of a hypothetical airway with a 10 mm internal perimeter.
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specifically a higher prevalence of diabetes
(21%), CHD (25%), CHF (8%), and stroke
(10%) compared with those without anemia.
Mean follow-up time for exacerbation data
was 2.1 years (SD, 0.95).
Associations of Anemia with Clinical
Outcomes
Normocytic anemia was associated with several
clinical outcomes in those with COPD
(Table 2). After adjustment for covariates
including comorbidity burden, those with
anemia had lower 6MWD (mean difference,
261.4; 95% confidence interval [CI],285.1 to
237.8), higher SGRQ (mean difference, 3.9;
95%CI, 1.1–6.7), higher total CAT score (mean
difference, 1.3; 95% CI, 0.04–2.5), and higher
MMRC score (mean difference, 0.27; 95% CI,
0.1–0.4) compared with those without anemia.
Anemia was not associated with an increased
risk of exacerbations over follow-up. Anemia
was not significantly associated with any
CT phenotypes (data not shown). After
accounting for multiple comparisons
of outcomes, statistically significant associations
between anemia and 6MWD, FEV1 %
predicted, and MMRC were observed.
Sensitivity analysis performed including
those with micro- and macrocytic anemia and
adjusting for cardiometabolic comorbidities
did not substantially change the analysis results
(data not shown). Findings were similar when
hemoglobin was treated as a continuous
variable. For each 1-g/dl increment in
hemoglobin, there were statistically significant
increments in 6MWD (mean difference, 11.4;
95% CI, 6.1–16.7) and FEV1 % predicted
(mean difference, 1.7; 95% CI, 0.4–0.7) and
significant decreases in SGRQ (mean
difference,20.7; 95%CI,21.3 to20.04), CAT
(mean difference, 20.3; 95% CI, 20.6 to
20.006), number of severe exacerbations in the
past year (mean difference in number of
exacerbations, 20.04; 95% CI, 20.07 to
20.0096), MMRC (b,20.07; 95% CI,20.1 to
20.03), prewalk oxygen saturation (mean
difference, 20.3; 95% CI, 20.5 to 20.1),
and postwalk oxygen saturation (mean
difference, 20.4; 95% CI, 20.6 to 20.2) (see
Table E1 in the online supplement). Using
fractional polynomials and restricted cubic
splines and when excluding those with high
hemoglobin (.15 g/dl for females, .17
for males), the linearity of associations is
depicted in Figure 1, which displays the
adjusted linear associations of hemoglobinwith
1) total CAT, 2) number of severe
exacerbations in the past year, 3) 6MWD, and
4) SGRQ.With thesemethods, the associations
appeared to be linear in nature, with the
exception of 6MWD, which appeared to have
some nonlinearity particularly in the higher
range of hemoglobin, reflecting that the
effect of increasing hemoglobin attenuates
at the higher range.
Effect Modification by Cardiometabolic
Phenotype
Significant interactionswith the cardiometabolic
phenotype were identified in adjusted
models for several outcomes, with anemia
more strongly associated with outcomes
among individuals with the cardiometabolic
phenotype compared with those without
(Table 3). Specifically, the adjusted mean
6MWD difference was 85.9 m (95% CI,
2122.5 to 249.5) among those with the
cardiometabolic phenotype compared with
37.7 m (b, 237.7; 95% CI, 268.0 to 27.3)
among those without the cardiometabolic
phenotype (P value for interaction = 0.02).
Although anemia was not associated with
increased exacerbation risk in the overall
cohort, anemia was associated with
increased number of any exacerbations
(mean difference in number of any
exacerbations, 0.3; 95% CI, 0.004–0.6)
and severe exacerbations (mean difference
in number of severe exacerbations, 0.2;
95% CI, 0.04–0.4) among those with the
cardiometabolic phenotype, with weaker
associations among those without the
phenotype (for all interactions, P value for
interaction, 0.10).
Associations with Serum Biomarker
Levels
Biomarker data were available for a
subgroup of participants (n = 1,042, 74 with
normocytic anemia). After correction for
multiple comparisons and adjustment for
covariates, anemia was associated with
higher CRP (adjusted mean difference, 7.0;
95% CI, 4.4–9.6), sRAGE (adjusted mean
difference, 1.4; 95% CI, 0.8–1.9), and CDH1
(adjusted mean difference, 1,213.2; 95% CI,
832.9–1,593.6) (Table E2). There was
evidence of effect modification by the
cardiometabolic phenotype with stronger
associations of anemia with sRAGE, CDH1,
IL-15, and ApoA4 among those with the
cardiometabolic phenotype compared with
those without (P for interaction, 0.1)
(Table E3).
Discussion
In this analysis of the large cohort of adults
with COPD in SPIROMICS, normocytic
anemia was a prevalent condition and
associated with adverse outcomes, including
low exercise capacity, health status measured
by SGRQ score, and increased dyspnea.
In the COPD population, those with
normocytic anemia had a significantly
higher burden of cardiac and metabolic
comorbidities, and not only was the
association of anemia with poor outcomes
independent of these comorbidities, but
unexpectedly, anemia appeared to have
Table 2. Associations of normocytic anemia with outcomes
No. Included
in Model
Coefficient 95% CI P Value
6MWD 1,631 261.4 285.1 to 237.8 ,0.01
FEV1 % predicted 1,719 26.7 210.8 to 22.7 0.01
SGRQ 1,618 3.9 1.1 to 6.7 0.01
Total CAT 1,647 1.3 0.04 to 2.5 0.04
No. of exacerbations in past year 1,719 0.1 20.04 to 0.3 0.14
No. of severe exacerbations in
past year
1,719 0.1 0.01 to 0.3 0.03
MMRC 1,710 0.3 0.1 to 0.4 0.01
Prewalk oxygen saturation 1,641 0.9 0.1 to 1.7 0.02
Postwalk oxygen saturation 1,627 1.4 0.4 to 2.4 0.01
Exacerbations over follow-up, IRR 1,625 1.1 0.8 to 1.4 0.59
Severe exacerbations over
follow-up, IRR
1,625 1.2 0.8 to 1.8 0.49
Definition of abbreviations: 6MWD= 6-minute walk distance; CAT =COPD Assessment Test; CI =
confidence interval; FEV1 = forced expiratory volume in 1 second; IRR = incidence rate ratio; MMRC =
Modified Medical Research Council; SGRQ= St. George’s Respiratory Questionnaire.
All regressionmodels adjusted for age, sex, race, FEV1% predicted, current smoking status, education
level, and comorbidity count. Odds ratios were estimated by adjusted logistic regression. Incident rate
ratios were estimated by adjusted zero-inflated negative binomial regression.
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stronger associations among those with
cardiac and metabolic comorbidities
compared with those without. Finally,
differing levels of select biomarkers found in
those with normocytic anemia suggest that
anemia may be associated with a specific
subphenotype of COPD with a higher level
of inflammation and epithelial injury,
associated with poor clinical outcomes.
Among those with anemia, there was a
significantly higher burden of comorbidities,
suggesting that anemia is likely part
of a larger phenotype of increasing
systemic illness and comorbidity burden.
Interestingly, the group with anemia had a
higher proportion of African Americans
and lower educational attainment, further
suggesting that anemia is likely part of a
larger systemic and environmental picture
that cannot be explained by COPD alone.
Regardless, the finding of worse outcomes
among anemic individuals with COPD is
consistent with findings of previous smaller
studies. Anemia has been associated with
mortality in a wide range of severity of
COPD including stable outpatients (5),
inpatients with acute exacerbations (25),
and those with respiratory failure on
mechanical ventilation (26). One previous
study showed that anemia of chronic disease
was associated with dyspnea and poor
circulatory efficiency in COPD, shown by
significantly lower peak oxygen uptake and
peak work rate on cardiopulmonary exercise
testing (27), suggesting a mechanistic link
between low hemoglobin and oxygen
carrying capacity with reduced exercise
capacity. Demonstrating the association
of anemia with impairment in exercise
capacity and heightened symptoms such as
dyspnea in a large, well-characterized cohort
such as SPIROMICS is an important step in
establishing the impact of anemia on disease
burden in COPD.
A key finding was of heightened
dyspnea among individuals with COPD
having comorbid anemia. It is possible that
those with respiratory limitation such as
individuals with COPD are more likely to be
burdened by comorbid anemia, particularly
regarding symptoms commonly thought to
impact individuals with respiratory disease,
such as exercise limitation and dyspnea.





















































































Figure 1. Adjusted associations of continuous hemoglobin with selected outcomes of interest. (A) Total CAT score; (B) number of severe exacerbations in
the past year; (C ) 6-minute walk distance; (D) SGRQ. Dotted lines indicate 10th and 90th percentiles for hemoglobin distribution, and the dashed line
indicates the median for hemoglobin distribution. CAT = COPD Assessment Test; SGRQ= St. George’s Respiratory Questionnaire.
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individuals with COPD having anemia had
lower peak VO2 during maximal cycle
ergometer testing, suggesting that anemia
physiologically impacts individuals with
COPD to drive symptoms such as dyspnea
and exercise limitation (4). The study by
Ferrari and colleagues is consistent with the
current study in demonstrating a significant
decrement in exercise capacity despite the
degree of anemia being relatively mild.
Other factors may also contribute, such as
increased respiratory rate and depth of
inspiration, which in normal individuals
could lead to the sensation of exertional
dyspnea (28) and in those with COPD
heighten existing exertional dyspnea.
Individuals with COPD and comorbid
anemia also had a significantly higher
burden of comorbid conditions. Another
study also showed a high prevalence of
cardiac and metabolic comorbidities in
individuals with COPD and anemia (9). It is
important to note that the adverse effects of
anemia were independent of the impact
of overall comorbidity burden including
comorbid cardiac and metabolic diseases
specifically, which are known to cause
significant morbidity in patients with COPD
(29, 30). Taking these findings further,
there was a synergistic effect of the presence
of both comorbid cardiac/metabolic
conditions and anemia, with anemia having
a worse impact among those with a high
burden of comorbid cardiac and metabolic
conditions. In the subjects with these
comorbidities, anemia had a stronger
adverse association with exercise capacity,
respiratory health status, and exacerbation
risk. This may be explained by worsened
oxygen delivery to tissues due to both
decreased cardiac output and oxygen
carrying capacity. In addition, anemia may
lead to further adverse impacts on cardiac
or vascular (micro or macro) function,
contributing to worse morbidity in patients
with COPD who have concomitant cardiac
disease. Interestingly, anemic patients with
COPD had a lower prevalence of current
smoking than those without anemia.
Although the etiology for this finding is not
clear, it is possible that the higher burden
of comorbid chronic disease, symptom
burden, and overall morbidity are associated
with increased prevalence of smoking
cessation.
This study’s findings of a higher level of
certain biomarkers in the group with anemia
suggest possible mechanisms for the adverse
impacts of anemia on COPD outcomes
as well as further identify a subphenotype
of individuals with COPD suffering from
anemia, comorbidity burden, and systemic
inflammation. Previous studies have
described possible systemic inflammatory
phenotypes of COPD in those with a high
prevalence of comorbid chronic conditions
(8–10). Garcia-Aymerich and colleagues
showed in a subgroup having a high burden
of comorbid chronic diseases and systemic
inflammation, but less substantially impaired
airflow obstruction, that exercise capacity
was similarly impaired in comparison with a
group having less comorbidity but more
substantial airflow obstruction (8). However,
anemia was not specifically explored
regarding its contribution to outcomes and
phenotyping in these studies; and our
results suggest that anemia may have
an additive effect to other comorbid
conditions.
Individuals with anemia had higher
levels of C-reactive protein, previously
shown to be associated with systemic
inflammation in COPD (8, 9). In addition,
two biomarkers were differentially
expressed not only between those with and
without anemia but also between those with
and without the cardiometabolic phenotype:
sRAGE and CDH1. The soluble receptor for
advanced glycation end-products (sRAGE)
is a marker of systemic inflammation that
has been traditionally associated with
metabolic diseases such as diabetes (31, 32),
has also more recently been studied in
populations with COPD where sRAGE has
been inversely associated with emphysema
severity (31). This analysis finds that not only
are anemia and cardiometabolic
comorbidities independently associated with
sRAGE but that the existence of both together
is associated with an even greater elevation
of sRAGE levels. These findings help to
establish anemia as an independent
and important correlate of systemic
inflammation, which in turn appears to
be part of a larger systemic inflammatory
subphenotype of COPD having a high
burden of comorbid chronic disease (8–10).
This analysis further demonstrates that
anemia is one of several possible independent
factors that contribute to the adverse
outcomes noted in this subgroup.
The consistent finding of higher serum
E-cadherin levels in those with anemia as
well as the positive interaction between
anemia and cardiometabolic phenotype
for E-cadherin levels is more difficult to
understand given the limited information
currently available about the role of serum
E-cadherin levels in COPD. E-cadherin is
a component of epithelial cells adherens
junctions, which allow for organization
of membrane proteins (32). The role of
Table 3. Associations of normocytic anemia with outcomes, based on subgroups
Group with Two or More Cardiometabolic
Comorbidities (n = 644)




95% CI P Value Difference in
Outcome Based on
Anemia Status
95% CI P Value P-int
6MWD 286.0 2122.5 to 249.5 ,0.01 237.7 268.0 to 27.3 0.02 0.02
Exacerbations in past year
(continuous, b)
0.3 0.004 to 0.6 0.047 20.03 20.3 to 0.2 0.83 0.04
Severe exacerbations in
past year (continuous, b)
0.2 0.04 to 0.4 0.02 0.04 20.1 to 0.2 0.65 0.06
Definition of abbreviations: 6MWD= 6-minute walk distance; CI = confidence interval; P-int = P value for interaction.
All models adjusted for age, sex, race, FEV1 % predicted, current smoking status, and educational level.
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E-cadherin in COPD is not clear, but
decreased expression of E-cadherin on the
epithelium is associated with a higher risk
for development of COPD in the setting
of cigarette smoke exposure (33–36).
Analysis of the SPIROMICS cohort
showed that higher serum E-cadherin
levels were associated with lower percent
emphysema (37). It is possible that
increased lung inflammation and epithelial
injury leads to lower E-cadherin levels
specifically in the epithelium, but higher
released or soluble levels of E-cadherin.
The findings of higher levels of serum
E-cadherin in COPD participants with
anemia are intriguing, particularly taken
with concurrent findings of a trend for less
emphysema in this group. Regardless of the
mechanism, the strength and significance of
this association are compelling and worthy
of further study.
This study is subject to some
limitations. There are several factors that
likely confound the association of anemia
with outcomes in the population with
COPD, and as with any study not all factors
are measured. Accordingly, we have
made adjustments for many potential
confounding factors, and have paid special
attention to confounding from comorbid
chronic disease in our adjustments, but
as with any epidemiologic study, residual
confounding is possible. Ultimately,
randomized trials targeted at both
identifying and treating anemia would be
required to provide further insight into
the importance of anemia and whether
improving hemoglobin would impact these
outcomes. Until such trials are conducted it
is difficult to know whether screening for or
treating anemia would be of value to patients
with COPD and should be incorporated in
clinical practice guidelines. In addition,
there is a high prevalence of normocytic
anemia in patients with chronic kidney
disease (CKD), but there are few biomarker
data on CKD such as serum creatinine
or glomerular filtration rate, and also
no data on carbon monoxide and
carboxyhemoglobin. In addition, there were
no data on erythropoietin levels or iron
indices, limiting our ability to determine the
underlying cause for anemia when present.
Regardless, the strength of the associations
noted between anemia and adverse
outcomes, as well as the independence of
these associations from other comorbid
chronic disease, is ultimately reassuring
that these findings are not merely due to
uncontrolled confounding related to
unmeasured chronic diseases such as CKD.
Several data points were also collected using
self-report, including report of exacerbation
events as well as the presence of comorbid
chronic disease and accordingly are subject
to some limitation. Another important
limitation is the overall low prevalence of
anemia. However, despite this limitation,
strong associations with outcomes were
found between anemia and clinical
outcomes. The results described largely
represent a cross-sectional analysis in which
exposures and outcomes were ascertained
at the same point in time; we are therefore
limited in inferring causality or directionality
of the observed associations due to the
unknown temporal ordering of exposure and
outcome. Finally, a small proportion of
people having anemia had microcytic or
macrocytic anemia, and because of this small
proportion as well as the hypothesis that the
etiology driving these different types of
anemia would be different than those causing
normocytic anemia, these individuals were
not included in the main analysis. However,
sensitivity analyses were performed including
these individuals, and the results were
minimally changed.
In conclusion, in this large, multicenter
study, normocytic anemia is shown to be
strongly associated with adverse functional
measures and outcomes in COPD, and
this association appears to be independent
of comorbid chronic disease, which is
prevalent in the group with anemia. Also,
the biomarker analysis suggests a few
possible mechanisms, such as increased
systemic inflammation and airway epithelial
injury, which may contribute to the adverse
impacts of anemia on COPD outcomes.
Ultimately, anemia could be one of
several independent contributors to
adverse outcomes in the subgroup of
individuals with COPD having high levels of
systemic inflammation and comorbidity
burden. This analysis is an important
step in establishing the scope of the
problem of anemia in COPD so that
future studies can understand which
populations are at highest risk and could
best be targeted for screening and
intervention. n
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